Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (146)	12/11/2002 12:42:58 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

GERN Is having a good move today after reporting that its telomerase inhibitor, GRN163, continues to show "efficacy without toxicity" in multiple cancer animal models. It has reported positive data from its telomerase-based cancer treatment programs at three scientific meetings so far this month. Besides the good reports on GRN163 it has also showed good results with its in vivo therapeutic vaccine and oncolytic virus at UCSF "War on Cancer" symposium on December 7,the ASH Meeting in PA on December 9 and the AACR conference in in SFon December 10. It has also reported preliminary results of its Phase 1 trial of an ex-vivo telomerase-based cancer vaccine at Duke. The stock still needs to close above its November 11 H of 4.25 before it can try for its Octobe 2 H at 4.43 and its September 12 H at 4.92 (The July29-July30 double top at the 5.58 level is somewhat farther out.<g>) bigcharts.marketwatch.com bigcharts.marketwatch.com But the stock hs shown good support at the $3.60 level and from a longer term perspective the R/R appears favorable. bigcharts.marketwatch.com The insiders hold only around 1%.They have reported higher loss and lower revenues after termination of the agreement with Pharmacia and costs from their acquisition of research technology from Lynx Therapeutics. Bernard

To: Jibacoa who wrote (146)	12/19/2002 11:41:50 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

SQNM Is up only 7.25% after announcing the publication in the Proceedings of the National Academy of Sciences of its method for conducting high-density genome-wide scans using pooled DNA samples. (It will be in the PNAS December 24th edition.) SQNM has now completed 8 scans for genes associated with skin cancer, breast cancer, adult-onset diabetes, high HDL levels, osteoarthritis, lung cancer, schizophrenia and age-related disease and is filing for intellectual property protection for its discovery results. According to Dr. Braun:"More importantly, as we have further defined targets coming out of the initial scans through additional statistical and genetic analyses, we are finding that commercially important targets are often within defined and characterized protein families and pathways, making them tractable for rapid drug development. As we further explore and characterize the cellular and functional biology, we remain confident that we will deliver approximately 20 genetically and functionally validated drug targets for major human diseases by the end of 2003." Will see if the stock can get back above its 2.35 resistance next week.<g> siliconinvestor.com I will just keep buying some on any dips.<g> Bernard